Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06603428
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Functional Outcome in Operative and Nonoperative Management in Isolated Greater Tuberosity Fracture of Humerus Bone
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Functional Outcome in Operative and Nonoperative Management in Isolated Greater Tuberosity Fracture of Humerus Bone cohort Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Constant score for functional outcome in operative and non-operative management in isolated greater tuberosity fractures of humerus bone
Detailed Description:
Fractures of the greater tuberosity GT often occur with more complex proximal humerus fractures and are less frequently observed as an isolated pathology Only 14-20 of proximal humerus fractures are isolated lesions of the GT Up to 30 of these fractures are associated with anterior glenohumeral dislocations According to Neer a displacement of the fragment 5mm and 30 or 3 mm of displacement in active patients involved in frequent overhead activity is believed to be an indication for operative treatment However indication for all other fractures had managed by nonoperative treatment is unclear Currently there is a lack of evidence in the literature to support either conservative or operative treatment strategies in GT humerus fractures The fracture type and the etiology of the fracture impact the decision- making and the final outcome also remains unclear age of more than 65 years as an important risk factor for secondary displacement in the conservative management of fractures of the greater tuberosity Furthermore fracture type and shoulder joint dislocations were factors associated with show increased relative risks for secondary fragment displacement
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None